Goldman Sachs Starts Sagimet at Sell, Sees 35% Downside Into AURORA
The bank says AURORA endpoints and teen compliance may not match China’s Phase 3 results.
The bank says AURORA endpoints and teen compliance may not match China’s Phase 3 results.
Investors are watching liability and damages in Nektar’s breach case against Lilly, a key swing factor for the Rezpeg program. Analysts still see damages as the hard issue.
Guggenheim raised Editas Medicine to Buy with a $5 target, citing EDIT-401’s potential in high-LDL ASCVD patients as its first human trial nears.
Doctors see 35%–40% U.S. share; peak sales estimate raised to about $400 million.
Prostate data look filing-ready, cash is $201.6M, and analysts see ~66% upside.
Helus Pharma sold off Friday after Barclays’ $35 initiation. The bank says APPROACH data are not the sole basis for its rating.